Long | ATOS NASDAQ:ATOS
Possible Scenario: Long
Target Prices TP1:3$, TP2: 5$, TP3: 7$
Timeframe: October 2023
Evidence: Price Actions, Money Flow
0%
0%
0%
0%
0%
About Atossa Therapeutics, Inc
Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Steven C. Quay
Website
atossatherapeutics.com
Headquarters
Seattle
Employees
11
Founded
2008
ISIN
US04962H5063
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform about breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
ATOS | InformativeNASDAQ:ATOS
I anticipate a pullback to $0.85 as the Relative Strength Index (RSI) indicates an overbought condition. Based on Elliott Waves theory, a correction is expected, followed by the emergence of the fifth leg.
Following the pullback, if the price surpasses the psychological resistance le
Atossa Therapeutics*risky but the reward…*
Trawling through the Nasdaq at the 11th hour before a major correction reveals a number of interesting opportunities where the success of tech stocks have overshadowed the less successful of late.
This trade idea is 100% technical without focus on the fundamentals. Atossa
ATOS amazing risk reward for longs! should see a bounce here we can easily do a triple bottom bounce off extreme support now, targeting 1.63-2.81-4.28 on a bounce with SL below extreme support zone.
can be a short play if support breaks as well
Target $ 2.78Atossa Therapeutics (ATOS) said Wednesday it has completed enrollment in part B of its phase 1/2a trial of drug candidate AT-H201 in Australia.
AT-H201 is being developed as an inhalation therapy for moderately to severely ill hospitalized COVID-19 patients and for "long-haul" patients with post-in
ATOS Weekly Shaping UpWe can see that the weekly chart is showing some exhaustion on the sell pressure. The daily has a bit of a heartbeat today breaking over the 20ema/ma.
Looking to see the weekly SARs flip underneath to support price, and a break over the T Line (EMA8) on the weekly to confirm a trend change.
If th
ATOS: no support for new uptrendHead and Shoulders pattern from earlier this year almost fully manifested (see my previous post below)
Next support is around 2.00 and if that does not hold we are looking at 1.5 and 0.8
our beloved $ATOS *This is not financial advice, so trade at your own risks*
*My team digs deep and finds stocks that are expected to perform well based off multiple confluences*
*Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management*
$ATOS rema
ATOS Deep Crab Pattern- Looks like ATOS has formed a bullish deep crab pattern
- might move lower if we don't break 2.88 and define as support
- potential bottom if we break current low -> 1.79
ATOS Journey to +20$- ATOS bounced of 200 SMA
- Low Volume indication of bottom -> Bullish Reversal
- Currently in ascending triangle -> Target 4.20 $
- MACD green
- Bollinger Bands contracting
- Road to +20$ has started!
See all ideas
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.
Gain new superpowers
Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn moreCurated watchlists where ATOS is featured.
